<DOC>
	<DOCNO>NCT01453881</DOCNO>
	<brief_summary>Adequate pharmacological treatment control symptoms asthmatic . Pressurized meter dose inhaler ( pMDI ) use drug delivery device . Valved hold chamber different type size also develop use combination pMDI . The therapeutic efficacy treatment depend amount inhaled particle . The chamber optimize lung deposition obviate lung-hand coordination retain large particle . The aim study compare efficacy fine particle combination pMDI Beclomethasone/Formoterol asthma control , without aid spacer patient without adequate asthma control medium high-dose inhaled steroid associate long act beta adrenergic drug . The hypothesis clinical efficacy difference two form drug administration .</brief_summary>
	<brief_title>Fine Particle pMDI Formoterol/Beclomethasone Asthmatics With Without Spacer : Comparative Efficacy Evaluation</brief_title>
	<detailed_description>This randomize , parallel control study blind outcome evaluation compare efficacy fine particle combination Beclomethasone/Formoterol administer without valved hold chamber ( Vortex , Pari Innovative Manufacturers , VA - USA . Eligible asthma patient begin 2-weeks run-in period optimize control medication use learn correct relief pMDI use without hold chamber . After run-in , patient non-controled asthma symptom ( ACT score 19 ) spite use medium high dose inhale steroid LABA association able use correctly pMDI randomize ( block-randomization ) receive test medication combination use without spacer device ( VORTEX ) . Patients evaluate 30 60 day . At day 15 ( + , - 2 ) 45 ( + , - 2 ) incentive phone call . ACT score ( translate validate portuguese - Brazil ) , FEV1 ( Kit-Micro spirometer , Cosmed , Italy ) , pMDI use clinical evaluation obtain initial visit ( visit 0 ) , randomization visit ( visit 1 ) 30 60 day ( visit 2 3 ) . Extra-medication allow run-in period inhale beta-2 bronchodilator relief treatment period inhale beta-2 agonist relief systemic steroid exacerbation , antibiotic need . Endpoint evaluation proceed treatment blind investigator.In order keep concealment , evaluation hold different room patient instructed comment treatment . Subjects exclude treatment period case severe asthma exacerbation ( hospital ICU recovery systemic steroid use 5 day ) . They exclude also case concomitant ailment discretion attend physician . These patient exclude per-protocol evaluation describe . Sample size calculate take account relevant ACT score difference 3 point SD 4.4 ( SCHATZ M et . Asthma Control Test : reliability , validity , responsiveness patient previously follow asthma specialist . J Allergy Clin Immunol 2006 ; 117:549-56 ) . In order able detect difference α β errors 5 % 20 % respectively , investigator calculate 32 patient per group . Statistical analysis carry accord data distribution professional statistician .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>1 . Adult , age 18 65 year , sex ; 2 . Clinical diagnosis moderate severe persistent asthma ; 3 . Nonsmoker ; 4 . Agree participate sign Informed Consent ; 5 . ACT Score &lt; = 19 6 . FEV1 &lt; = 80 % predict ; 7 . History response FEV1 great 10 % ; 8 . Patients already use Inhaled steroid medium high dos ( Beclomethasone , budesonide , fluticasone ) longaacting beta2 agonist ( formoterol salmeterol ) 9 . Proper use metereddose inhaler ( orientation ) 1 . Patient diagnose Chronic Obstructive Pulmonary Disease ( COPD ) ; 2 . Current smoker stop less 10 year ; 3 . Patients history recent nearfatal asthma ( le 12 month ) ; 4 . Patients history recent asthma hospitalization ( last 6 month ) ; 5 . Patients airway infection symptom less 4 week ; 6 . Participation experimental study 1 ( one ) year selection visit ; 7 . Hospitalization reason 8 week selection visit ; 8 . History liver , cardiac , renal , pulmonary gastrointestinal disease , epileptic , psychiatric hematologic disorder , uncontrolled hypertension , rheumatology/orthopedic disorder interferes pMDI use ; 9 . Patients unable properly use pMDI selection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>pMDI</keyword>
	<keyword>Beclomethasone</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Efficacy</keyword>
</DOC>